 |
 |
   |
 |
 |
|
- Antioxidants Offer Pain Relief In Patients With Chronic Pancreatitis
Antioxidant supplementation was found to be effective in relieving pain and reducing levels of oxidative stress in patients with chronic pancreatitis (CP), reports a new study in Gastroenterology. CP is a progressive inflammatory disease of the pancreas in which patients experience abdominal pain (in early stage) and diabetes and maldigestion (in late stage).
- Introducing Abstral(R). Innovative Drug Delivery Technology For Rapid Breakthrough Cancer Pain Management
Abstral® is an important new treatment option for inadequately controlled breakthrough cancer pain (BTcP) in opioid-tolerant cancer patients. The Abstral formulation delivers the analgesic power of fentanyl in a fast dissolving sublingual tablet. Abstral provides rapid relief of BTcP from 10 minutes1, provides predictable dosing2,3 and is convenient and easy to use.
- King Pharmaceuticals Initiates Phase II Clinical Trial Evaluating T-62 As A Treatment For Neuropathic Pain
King Pharmaceuticals, Inc. (NYSE: KG) today announced that it has initiated the Phase II clinical trial program evaluating the efficacy and safety of T-62, an oral tablet formulation, the Company's investigational drug for the treatment of neuropathic pain. Dr. Eric Carter, Chief Science Officer of King, stated, "T-62, a new chemical entity, is an adenosine A1 allosteric enhancer that increases the effectiveness of the body's endogenous adenosine to treat neuropathic pain.
- Study First To Pinpoint Why Analgesic Drugs May Be Less Potent In Females Than In Males
Investigators at Georgia State University's Neuroscience Institute and Center for Behavioral Neuroscience are the first to identify the most likely reason analgesic drug treatment is usually less potent in females than males. This discovery is a major step toward finding more effective treatments for females suffering from persistent pain.
- PAION And ERGOMED Complete Enrolment Of Phase IIa Study With CNS 5161 In Opioid-Refractory Cancer Pain
The biopharmaceutical company PAION AG (ISIN DE000A0B65S3; Frankfurt Stock Exchange, Prime Standard: PA8; London AIM: PAI) and ERGOMED Clinical Research Limited today announce the completion of an open-label, single-centre Phase IIa study with PAION's intravenous NMDA receptor antagonist CNS 5161. The study has been completed by PAION and ERGOMED under a Revenue Sharing and Co-Development Agreement signed in July 2006.
- Premature Babies Have Altered Sensory Responses In Later Life
Premature infants who need intensive care or surgery are less sensitive to thermal (hot and cold) sensations later in life, according to research conducted at UCL (University College London). The study, published in the journal Pain, suggests that pain and injury related to major medical interventions in early development may alter how children respond to painful stimuli much later in life.
- Humans Make Their Own Salicylic Acid, Aspirin's Active Principle, Say UK Scientists
Scientists in the United Kingdom are reporting new evidence that humans can make their own salicylic acid (SA) - the material formed when aspirin breaks down in the body. SA, which is responsible for aspirin's renowned effects in relieving pain and inflammation, may be the first in a new class of bioregulators, according to a study scheduled for the Dec. 24 issue of ACS' biweekly Journal of Agricultural and Food Chemistry. In the report, Gwendoline Baxter, Ph.D.
|  |
 |  |
